Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2Unknown 2Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 12Other solid neoplasm 8Tumor-Agnostic 7Genitourinary 7Gynecologic 5Other hematologic neoplasm 3Thoracic 2Gastrointestinal 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × talazoparib × Thoracic × Clear all
NCT04173507 2024-09-03

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡